Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Genmab ( (GMAB) ) just unveiled an update.
On May 19, 2025, Genmab A/S announced the execution of transactions under its share buy-back program, initiated on March 25, 2025, to repurchase up to 2.2 million shares. The program, expected to conclude by July 10, 2025, aims to reduce capital and fulfill commitments under the Restricted Stock Unit program. From May 12 to May 16, 2025, Genmab repurchased 313,080 shares, bringing the total accumulated under the program to 1,983,650 shares. This strategic move is aligned with the company’s efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance, stable profitability, and effective cash flow management significantly bolster its stock score. While technical indicators suggest caution with current stock momentum, the company’s solid earnings call and reasonable valuation further support a positive outlook. The overall score reflects these strengths, tempered by slight concerns over dependency on key products and short-term market fluctuations.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. Established in 1999 and headquartered in Copenhagen, Denmark, the company has a global presence across North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators, aiming to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,500,381
Technical Sentiment Signal: Sell
Current Market Cap: $12.16B
For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.